Atovaquone-induced therapeutic rewiring of melanoma metabolism
Ponce, M. B.; Heaton, A. R.; Burkard, S.; D'Amato, A.; Boonpattrawong, N.; Skala, M. C.; Patankar, M. S.; Barroilhet, L.
Show abstract
Melanoma continues to be the deadliest form of skin cancer, emphasizing the need for new therapeutic strategies. Targeting tumor metabolism, particularly oxidative phosphorylation (OXPHOS) has emerged as a promising approach due its role in melanoma tumor survival, metastasis, and treatment resistance. In this study, we investigate the metabolic and antitumor effects of atovaquone, an FDA-approved and safe OXPHOS inhibitor that has not been previously tested in melanoma. We show that atovaquone rapidly and effectively inhibits OXPHOS and impairs glycolysis in melanoma, leading to metabolic reprogramming observed via metabolic imaging and marked depletion in energy (ATP) stores. Atovaquone also induces oxidative stress, evidenced by increased reactive oxygen species levels, DNA damage, and upregulation of antioxidant proteins. Moreover, atovaquone reduced melanoma cell viability and migration in vitro, and slowed tumor growth in vivo. Notably, these effects were observed in both BRAF-wild-type and mutant melanoma models, suggesting its potential as an effective treatment across different subtypes. Our study identifies atovaquone as a metabolic disruptor with antitumor activity against melanoma, supporting further investigation as a repurposed therapeutic strategy.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies. 96%
- Epidermal Growth Factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium 94%
- Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone 93%
Similar papers in this journal
- GABA(A) receptor activation drives GABARAP-Nix mediated autophagy to radiation-sensitize primary and brain-metastatic lung adenocarcinoma tumors 94%
- In vivo optical metabolic imaging of long-chain fatty acid uptake in orthotopic models of triple negative breast cancer 94%
- The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration. 93%
Similar papers in this journal
- A high-content microscopy drug screening platform for regulators of the extracellular digestion of lipoprotein aggregates by macrophages 92%
- Therapeutic assessment of targeting ASNS combined with L-Asparaginase treatment in solid tumors and investigation of resistance mechanisms 92%
- Target-driven design of a coumarinyl chalcone scaffold based novel EF2 Kinase inhibitor suppresses breast cancer growth in vivo 91%
Similar papers in this journal
- Targeting the glucose-insulin link in head and neck squamous cell carcinoma induces cytotoxic oxidative stress and inhibits cancer growth 93%
- p300 KAT regulates SOX10 stability and function in human melanoma 93%
- LNS8801: An enantiomerically pure agonist of the G protein-coupled estrogen receptor suitable for clinical development 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.